MNK MNK マリンクロット

 MNKのチャート


 MNKの企業情報

symbol MNK
会社名 Mallinckrodt Plc (MNK マリンクロット)
分野(sector)   
産業(industry)   
業種 医薬品   医療関連(Health Care)
概要 事業概要 マリンクロット(Mallinckrodt public limited company)は世界的な特殊医薬品会社である。同社はブランド付きとジェネリックスペシャリティ医薬品医薬品有効成分(API)と画像診断薬の開発・製造・マーケティング・販売を行っている。同社はAPI製品を使用してジェネリック医薬品を製造して、その他製薬会社に販売する。同社は2つの事業区分を通して運営している。スペシャルティ医薬品事業はそのブランドビジネスを通して、「EXALGO」(ヒドロモルフォン塩酸)放錠及び「GABLOFEN」(バクロフェン注射)を含める医薬品を開発・製造・販売している。グローバルメディカルイメージング事業は造影剤とデリバリーシステム(CMDS)を開発・製造・販売している。平成25年6月28日、Covidien plcは医薬品事業の分離を完了し、それを同社に譲渡した。  マリンクロットはアイルランドのバイオ医薬品・画像診断剤メ―カ―。特殊医薬品部門はブランド医薬品、バイオ医薬品に加え、オピオイドやアセトアミノフェンなどの医療用麻薬を成分とする医薬品原薬を扱う。グロ―バル医療画像部門は造影剤、ドラッグデリバリ―システム、放射性医薬品を開発、製造、販売。  Mallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines. The Specialty Generics segment relates to specialty generic drugs, active pharmaceutical ingredients, as well as external manufacturing. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin.
本社所在地 3 Lotus Park The Causeway Staines-Upon-Thames Surrey TW18 3AG GBR
代表者氏名 Mark C. Trudeau
代表者役職名 President Chief Executive Officer Director
電話番号 +44 1784-63-6700
設立年月日 41275
市場名 NYSE(ニューヨーク証券取引所)
ipoyear
従業員数 3700人
url www.mallinckrodt.com
nasdaq_url
adr_tso
EBITDA EBITDA(百万ドル) 1131.90000
終値(lastsale)
時価総額(marketcap)
時価総額 時価総額(百万ドル) 1815.39900
売上高 売上高(百万ドル) 3215.60000
企業価値(EV) 企業価値(EV)(百万ドル) 7558.09900
当期純利益 当期純利益(百万ドル) -3630.40000
決算概要 決算概要 BRIEF: For the fiscal year ended 28 December 2018 Mallinckrodt PLC revenues remained flat at $3.22B. Net loss before extraordinary items totaled $3.63B vs. income of $1.31B. Revenues reflect Other segment increase of 55% to $124.3M Europe/Middle EastAfrica segment increase of 6% to $256.8M also reflect United States segment decrease of 2% to $2.83B. Net loss reflects Corporate/Unallocated segment loss increase from $966.6M to $4.9B.

 MNKのテクニカル分析


 MNKのニュース

   Nuclear Medicine Equipment Market to Grow at a CAGR of 6.2% by 2026 with Leading Vendors CMR Naviscan, SurgicEye GmbH, Mallinckrodt, Neusoft Corporation, DDD-Diagnostic A/S, CANON MEDICAL SYSTEMS CORPORATION  2020/10/13 18:57:04 OpenPR
Nuclear Medicine Equipment Market By Product (Single Photon-Emission Computed Tomography (SPECT), Hybrid Pet, Planar Scintigraphy), Application (Cardiology, Oncology, Neurology, Other Applications), End User (Hospitals, Imaging Centers, Academic and Research Centers, Other End Users), Geography (North America, South America, Europe, Asia-Pacific,
   St. Louis-based Mallinckrodt Files For Bankruptcy, To Pay Billions To Settle Lawsuits  2020/10/13 01:19:35 Flipboard
St. Louis-based pharmaceutical company Mallinckrodt on Monday filed for bankruptcy after years of lawsuits alleging the drug company shared blame for the opioid epidemic. State, local and tribal governments have sued Mallinckrodt and other opioid manufacturers, saying the companies pushed the painkillers to patients despite knowing how addictive and dangerous they were.
   Mallinckrodt looks to fend off 'police power' action amid bankruptcy  2020/10/12 19:09:52 Reuters
Mallinckrodt PLC on Monday moved to block hundreds of state and local governments from advancing ongoing opioid-related litigation against it, looking to ensure that its bankruptcy can proceed without interruption.
   Largest Maker Of Generic Opioids Files For Bankruptcy During Lawsuits Alleging Role In Addiction Epidemic  2020/10/12 18:25:38 The Daily Caller
Mallinckrodt, the largest maker of generic opioids, filed for bankruptcy as it faces billions of dollars in lawsuits over its role in fueling the opioid crisis.
   Informative Report on Codeine Market Analysis by Regions, Share, Top Key Players (J&J, Taiji, Mallinckrodt, TEVA, Medreich, Sanofi Aventis, Cipla, Novartis, Mylan) and Forecasts to 2025  2020/10/12 16:08:58 OpenPR
The Global Codeine Market is comprehensively and Insightful information in the report, taking into consideration various factors such as competition, regional growth, segmentation, and Codeine Market size by value and volume. This is an excellent research study specially compiled to
   Zeichnen mit Buntstiften: Kreativwochenende auf der Gamburg  2020/09/17 09:36:02 Mainpost
Als Ersatz für die wegen Corona ausgefallenen Kreativwochenenden auf der Gamburg im Mai und Juni haben, hat sich die Kunstschule Gamburg kurzfristig entschieden, vom 3. bis 4. Oktober einen zusätzlichen Kurs anzubieten, wie es im Presseschreiben von Kursleiter Goswin von Mallinckrodt heißt.
   The Week Ahead In Biotech: Focus On Mallinckrodt FDA Decision, Conference Presentations  2020/09/06 17:25:13 Benzinga
After remaining steady in the first three sessions of the week ended Sept. 4, biotech stocks pulled back along with the broader market in a tech-induced sell-off. Barring anything COVID-19-related , the news flow was fairly light ahead of the Labor Day holiday. Amarin Corporation plc (NASDAQ: AMRN ) took a severe beating after losing a patent appeal related to its synthetic fish oil pill Vascepa. The stock lost over 40% during the week, attributable primarily to the adverse ruling and to a smaller extent to the market sell-off. Here are the key catalysts for the unfolding week. Conferences Citi's 15th Annual BioPharma Conference: Sept. 8-11 Wells Fargo 2020 Virtual Healthcare Conference: Sept. 9-10 Baird 2020 Global Healthcare Conference: Sept. 9-10 BTIG Virtual Biotechnology Conference: Sept. 10-11 66th Annual Meeting of the American Rhinologic Society, or ARS, (virtual event): Sept. 10-12 International Gynecologic Cancer Society, or IGCS, xDigital Annual Global Meeting: Sept. 10-13 2020 Psych Congress (virtual event): Sept.
   Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates  2020/09/01 22:05:07 Benzinga
August was a disappointing month as far as regulatory decisions are concerned. The FDA turned down several applications, citing different reasons. Notable among the candidates that received the thumbs down were rheumatoid arthritis investigational therapy filgotinib sponsored by Gilead Sciences, Inc. (NASDAQ: GILD ) and BioMarin Pharmaceutical Inc.'s (NASDAQ: BMRN ) investigational gene therapy for hemophilia A. That said, the month saw approvals of eight new molecular entities, taking the total for the year to 38. Here are the key PDUFA dates scheduled for September. Bristol-Myers Squibb Awaits Nod For Blood Cancer Maintenance Therapy Company: Bristol-Myers Squibb Co's (NYSE: BMY ) Type of Application: NDA Candidate: CC-486 Indication: Acute myeloid leukemia Date: Aug. 3 CC-486 is an investigational oral hypomethylating agent, for the maintenance treatment of adult patients with acute myeloid leukemia, who achieved complete remission or complete remission with incomplete blood count recovery.
   Mallinckrodt anuncia el Premio al Investigador 2020 sobre avances en inmunomodulación de FEC  2020/08/31 16:39:00 PR Newswire
-- El premio de 50.000 euros es para el Hospital Universitario de Lille en Francia para financiar la investigación sobre el posible impacto de la fotoféresis extracorpórea (FEC) sobre los procesos fibrosantes -- DUBLÍN, 31 de agosto de 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK),…
   Mallinckrodt gibt Vergabe des Investigator Award 2020 für weitere Fortschritte im Bereich der ECP-Immunmodulation bekannt  2020/08/31 10:43:00 PR Newswire
-- Die mit 50.000 € EUR dotierte Auszeichnung geht an das Universitätskrankenhaus in Lille in Frankreich, um Forschungen zu den potenziellen Auswirkungen der extrakorporalen Photopherese (ECP) auf Fibrosierungsprozesse zu finanzieren -- DUBLIN, 31. August 2020 /PRNewswire/ -- Mallinckrodt…
   Zeichnen mit Buntstiften: Kreativwochenende auf der Gamburg  2020/09/17 09:36:02 Mainpost
Als Ersatz für die wegen Corona ausgefallenen Kreativwochenenden auf der Gamburg im Mai und Juni haben, hat sich die Kunstschule Gamburg kurzfristig entschieden, vom 3. bis 4. Oktober einen zusätzlichen Kurs anzubieten, wie es im Presseschreiben von Kursleiter Goswin von Mallinckrodt heißt.
   The Week Ahead In Biotech: Focus On Mallinckrodt FDA Decision, Conference Presentations  2020/09/06 17:25:13 Benzinga
After remaining steady in the first three sessions of the week ended Sept. 4, biotech stocks pulled back along with the broader market in a tech-induced sell-off. Barring anything COVID-19-related , the news flow was fairly light ahead of the Labor Day holiday. Amarin Corporation plc (NASDAQ: AMRN ) took a severe beating after losing a patent appeal related to its synthetic fish oil pill Vascepa. The stock lost over 40% during the week, attributable primarily to the adverse ruling and to a smaller extent to the market sell-off. Here are the key catalysts for the unfolding week. Conferences Citi's 15th Annual BioPharma Conference: Sept. 8-11 Wells Fargo 2020 Virtual Healthcare Conference: Sept. 9-10 Baird 2020 Global Healthcare Conference: Sept. 9-10 BTIG Virtual Biotechnology Conference: Sept. 10-11 66th Annual Meeting of the American Rhinologic Society, or ARS, (virtual event): Sept. 10-12 International Gynecologic Cancer Society, or IGCS, xDigital Annual Global Meeting: Sept. 10-13 2020 Psych Congress (virtual event): Sept.
   Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates  2020/09/01 22:05:07 Benzinga
August was a disappointing month as far as regulatory decisions are concerned. The FDA turned down several applications, citing different reasons. Notable among the candidates that received the thumbs down were rheumatoid arthritis investigational therapy filgotinib sponsored by Gilead Sciences, Inc. (NASDAQ: GILD ) and BioMarin Pharmaceutical Inc.'s (NASDAQ: BMRN ) investigational gene therapy for hemophilia A. That said, the month saw approvals of eight new molecular entities, taking the total for the year to 38. Here are the key PDUFA dates scheduled for September. Bristol-Myers Squibb Awaits Nod For Blood Cancer Maintenance Therapy Company: Bristol-Myers Squibb Co's (NYSE: BMY ) Type of Application: NDA Candidate: CC-486 Indication: Acute myeloid leukemia Date: Aug. 3 CC-486 is an investigational oral hypomethylating agent, for the maintenance treatment of adult patients with acute myeloid leukemia, who achieved complete remission or complete remission with incomplete blood count recovery.
   Mallinckrodt anuncia el Premio al Investigador 2020 sobre avances en inmunomodulación de FEC  2020/08/31 16:39:00 PR Newswire
-- El premio de 50.000 euros es para el Hospital Universitario de Lille en Francia para financiar la investigación sobre el posible impacto de la fotoféresis extracorpórea (FEC) sobre los procesos fibrosantes -- DUBLÍN, 31 de agosto de 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK),…
   Mallinckrodt gibt Vergabe des Investigator Award 2020 für weitere Fortschritte im Bereich der ECP-Immunmodulation bekannt  2020/08/31 10:43:00 PR Newswire
-- Die mit 50.000 € EUR dotierte Auszeichnung geht an das Universitätskrankenhaus in Lille in Frankreich, um Forschungen zu den potenziellen Auswirkungen der extrakorporalen Photopherese (ECP) auf Fibrosierungsprozesse zu finanzieren -- DUBLIN, 31. August 2020 /PRNewswire/ -- Mallinckrodt…

 関連キーワード  (医薬品 米国株 MNK マリンクロット MNK )

 twitter  (公式ツイッターやCEOツイッターなど)